1.51
0.12 (8.24%)
| Previous Close | 1.40 |
| Open | 1.39 |
| Volume | 1,524,300 |
| Avg. Volume (3M) | 3,517,653 |
| Market Cap | 126,406,472 |
| Price / Sales | 3.48 |
| Price / Book | 2.03 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -758.05% |
| Diluted EPS (TTM) | -3.04 |
| Quarterly Revenue Growth (YOY) | 310.40% |
| Total Debt/Equity (MRQ) | 49.88% |
| Current Ratio (MRQ) | 3.08 |
| Operating Cash Flow (TTM) | -208.21 M |
| Levered Free Cash Flow (TTM) | -103.52 M |
| Return on Assets (TTM) | -36.80% |
| Return on Equity (TTM) | -140.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Editas Medicine, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.13 |
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.35% |
| % Held by Institutions | 54.01% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 4.00 (Baird, 164.90%) | Buy |
| Median | 3.50 (131.79%) | |
| Low | 3.00 (HC Wainwright & Co., 98.68%) | Buy |
| Average | 3.50 (131.79%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 13 May 2025 | 4.00 (164.90%) | Buy | 1.50 |
| HC Wainwright & Co. | 28 Apr 2025 | 3.00 (98.68%) | Buy | 1.58 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |